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Summary
Developmental studies support a common origin for
blood and endothelial cells, while studies of adult an-
giogenic responses suggest that the hematopoietic
system can be a source of endothelial cells later in
life. Whether hematopoietic tissue is a source of endo-
thelial cells during normal vascular development is
unknown. Mouse embryos lacking the signaling pro-
teins Syk and Slp-76 develop abnormal blood-lym-
phatic endothelial connections. Here we demonstrate
that expression of GFPSlp-76 in a subset of hemato-
poietic cells rescues this phenotype, and that deficient
cells confer focal vascular phenotypes in chimeric em-
bryos consistent with a cell-autonomous mechanism.
Endogenous Syk and Slp-76, as well as transgenic
GFPSlp-76, are expressed in circulating cells previ-
ously proposed to be endothelial precursors, support-
ing a causal role for these cells. These studies provide
genetic evidence for hematopoietic contribution to
vascular development and suggest that hematopoietic
tissue can provide a source of vascular endothelial
progenitor cells throughout life.
Introduction
Close spatial and temporal association (Sabin, 1920),
genetic studies (Shalaby et al., 1995; Stainier et al.,
1995), and studies of cultured embryonic stem cells
(Kennedy et al., 1997) support a common origin for
blood and endothelial cells during embryonic develop-
ment. Recent studies using adult animals have extended
this relationship with evidence that mature hematopoi-
etic stem cells can give rise to circulating cells that par-
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htmlticipate in adult vessel growth in response to angiogenic
stimuli (reviewed in Rafii and Lyden, 2003). This work
has revealed the possibility of a novel angiogenic mech-
anism with great therapeutic potential, but whether and
how hematopoietic cells contribute to normal vascular
growth and development remain unknown.
A primary difficulty in defining the hematopoietic cell
contribution to new vessel growth is accurately discrim-
inating between vascular endothelial cells of different
origins. In developing animals, lineage tracing experi-
ments using Cre recombinase suggest that the extent
of hematopoietic contribution to embryonic endothe-
lium may be low (Stadtfeld and Graf, 2005), but such
studies are descriptive and limited both by the choice
of the Cre driver (which may be either too restrictive
and not express in the appropriate hematopoietic pro-
genitor cells, or not restrictive enough and have ‘‘leaky’’
expression in mature endothelial cells regardless of their
origin) and by the ability to detect a potentially rare pop-
ulation of hematopoietic-derived endothelial cells in an
extensive vascular network. In mature animals, defini-
tive identification of hematopoietic origin has been
achieved through reconstitution of lethally irradiated an-
imals with hematopoietic tissue that stably expresses
a reporter gene to mark all cell progeny. Because mature
animals are not in an angiogenic state, however, this
tagging system must be coupled to the application of
potent but nonphysiologic angiogenic stimuli such as
the sudden cessation of blood flow (Asahara et al.,
1997), injection of tumor cells (Lyden et al., 2001), or di-
rect administration of angiogenic growth factors (Asa-
hara et al., 1999).
Such studies have yielded controversial and even
conflicting results regarding both the hematopoietic
cell requirement for different angiogenic responses
and the identity of the hematopoietic cell type required.
Bone marrow-derived progenitor cells that carry endo-
thelial cell markers have been identified in the blood of
mice and humans (Asahara et al., 1997) and experimen-
tal angiogenic responses have been shown to require
the recruitment of hematopoietic cells (Aicher et al.,
2003; Lyden et al., 2001), but whether such requirements
reflect a causal role for these rare precursor cells or for
another hematopoietic cell type is not established. In
particular, adult angiogenic models are associated
with, and may even require, recruitment of inflammatory
hematopoietic cell types such as tissue macrophages
that may be difficult to distinguish from endothelial cells
due to their infiltration into the vessel wall and/or expres-
sion of endothelial molecular markers (Grunewald et al.,
2006; Maruyama et al., 2005; Rabelink et al., 2004; Reh-
man et al., 2003; Ziegelhoeffer et al., 2004). Thus whether
and how hematopoietic cell precursors contribute to
physiologic vascular growth is not yet clear.
In the present study we have used functional, genetic
approaches to investigate the cellular mechanism for
the vascular endothelial phenotype that arises in mouse
embryos lacking Syk and Slp-76. Transgenic rescue
demonstrates a hematopoietic cell requirement for
Slp-76 signaling, while chimeric embryo studies reveal
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contribution to new lymphatic vessels confers blood-
lymphatic vascular mixing. These findings point to a de-
fect that arises from loss of signaling in hematopoietic
cells that function as endothelial precursors during em-
bryonic development, a conclusion supported by a de-
fect in a cognate cell population, circulating endothelial
precursor cells (CEPs), in surviving Slp-76-deficient an-
imals. These findings provide new evidence for hemato-
poietic cell contribution to normal vessel growth and
development.
Results
Generation of GATA1-GFPSlp-76 Transgenic
Animals that Express GFPSlp-76 in a Restricted
Number of Hematopoietic Cell Types
Studies of Slp-76 and Syk gene expression using in situ
hybridization failed to detect endothelial expression of
either gene in E11.5 or E14.5 embryos, time points at
which deficient embryos exhibit lymphatic vascular phe-
notypes (Abtahian et al., 2003). Flow cytometric analysis
of neonatal skin endothelial cells similarly failed to dem-
onstrate endothelial expression of these proteins (see
Figure S1A in the Supplemental Data available with
this article online). Thus, at the level of both mRNA and
protein, Syk and Slp-76 gene expression is detected in
hematopoietic cells but not in mature endothelial cells
in vivo.
To functionally discriminate between a requirement
for Slp-76 in hematopoietic and endothelial cells, we
adopted a complementation strategy to rescue Slp-76
expression in hematopoietic but not endothelial cells us-
ing a GATA1 minigene previously shown to restrict
transgene expression to a subset of hematopoietic line-
ages (McDevitt et al., 1997). Transgenic gain of function
is superior to conditional loss of function for this pur-
pose because coexpression of genes such as Tie-2
and Vav in hematopoietic stem cells and endothelial
cells drives gene excision in the mature cells of both lin-
eages in Cre-expressing transgenic mice (Constien
et al., 2001; Georgiades et al., 2002). To precisely follow
transgene expression, we generated transgenic mice
that expressed a GFPSlp-76 fusion protein (Figure S1B).
GATA1 is a transcription factor expressed in hematopoi-
etic stem cells (Sposi et al., 1992) and in a limited reper-
toire of differentiated hematopoietic cells including
erythrocytes, platelets, eosinophils, and mast cells (Mi-
gliaccio et al., 2003; Shivdasani et al., 1997; Whitelaw
et al., 1990; Yu et al., 2002), but not in lymphocytes, mac-
rophages, or endothelial cells (McDevitt et al., 1997). The
GATA1 minigene has been used previously to distin-
guish between hematopoietic and endothelial require-
ments for specific gene products such as the Scl/Tal-1
transcription factor and the erythropoietin receptor us-
ing a similar rescue strategy (Suzuki et al., 2002; Vis-
vader et al., 1998). Two GATA1-GFPSlp-76 transgenic
lines were characterized (Figure S1C). The studies re-
ported below utilized the higher expressing transgenic
line to optimize detection of GFPSlp-76, but identical re-
sults were obtained using both transgenic lines.
Transgene expression was first assayed using flow
cytometry of live cells obtained from postnatal animals
to detect GFPSlp-76. Among the hematopoietic line-ages, GFPSlp-76 was detected in platelets, erythro-
cytes, eosinophils, and a subset of lin2, Sca1+, c-kit+
stem cells, but not in T or B lymphocytes, macrophages,
neutrophils, NK cells, or dendritic cells (Figure 1A and
data not shown). GFPSlp-76 was also not detected in
peritoneal mast cells, a finding consistent with the re-
ported expression of a lacZ transgene using the same
GATA1 minigene (McDevitt et al., 1997). To determine
whether GATA1-GFPSlp-76 transgenic mice express
GFPSlp-76 in endothelial cells, neonatal skin cells
(known to contain both blood and lymphatic endothelial
cells) from wild-type, Tie2-GFP transgenic, and GATA1-
GFPSlp-76 transgenic animals were analyzed using flow
cytometry for expression of VE-cadherin (CD144), an en-
dothelial cell marker, and CD45, a cell surface protein
found on blood but not endothelial cells. Tie2-GFP
transgenic mice express GFP in a subset of vascular en-
dothelial cells but not in mature circulating cells (Mo-
toike et al., 2000). GFP+, CD144+ endothelial cells were
identified in the skin of Tie2-GFP but not GATA1-
GFPSlp-76 transgenic animals (Figure 1B). Conversely
GFP+, CD45+ hematopoietic cells were identified in the
skin of GATA1-GFPSlp-76 but not Tie2-GFP transgenic
animals (Figure 1B). Thus, GATA1-GFPSlp-76 trans-
genic animals express the GFPSlp-76 fusion protein
exclusively in stem cells, erythrocytes, platelets, and
eosinophils, and not in vascular endothelial cells
postnatally.
To determine the cellular sites of GATA1-GFPSlp-76
transgene expression in the developing embryo, flow
cytometry and antibody staining of embryo sections
were performed. Flow cytometry revealed GFP expres-
sion in CD45+, CD1442 blood cells but not in CD144+,
CD452 endothelial cells derived from E14.5 embryos
(Figure 1C). Immunohistochemical staining for GFP
identified GFP+ cells in the lumen of blood vessels and
in the fetal liver, the source of hematopoietic cells at
E14.5, but not in vascular endothelial cells (Figure 1D).
To better determine whether GFP+ cells might partici-
pate directly or indirectly in the formation of the early
lymphatic vessels, immunofluorescent studies were
performed to detect GFP+ cells in the region of the
LYVE1+ endothelial cells of the primitive lymph sacs in
E12.5 embryos. LYVE1+ endothelial cells are known to
line the primitive lymph sac and the dorsal aspect of
the cardinal vein, but not the aorta (Wigle et al., 2002).
While GFP+ cells were detected in the lumen of the car-
dinal vein and aorta, none were detected either in or next
to LYVE1+ endothelial cells (Figure 1E). Thus, GATA1-
GFPSlp-76 transgene expression is restricted to a
subset of circulating blood cells and is not detected in
endothelial or perivascular cells during early lymphatic
development, the time point at which embryos lacking
Syk or Slp-76 exhibit lymphatic vascular defects.
The GATA1-GFPSlp-76 Transgene Rescues Slp-76
Function in Platelets but Not in Neutrophils or T Cells
To test GATA1-GFPSlp-76 transgene function, we gen-
erated Slp-76-deficient animals that carried the
GATA1-GFPSlp-76 transgene (G1 rescue animals). Slp-
76 is required for signaling through the platelet collagen
receptor glycoprotein VI (GPVI) and Slp-76-deficient
platelets fail to secrete P-selectin (CD62) following ex-
posure to the strong GPVI agonist convulxin (CVX)
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hibited complete rescue of Slp-76-dependent platelet
CVX activation, with no change in platelet activation by
the G protein-coupled receptor agonist AYPGKF (an ac-
tivating peptide for protease-activated receptor 4;
Figure 2A).
Slp-76 is required for neutrophil release of superoxide
in response to integrin ligand binding (Newbrough et al.,
2003), as well as for T cell maturation in the thymus
(Clements et al., 1998). Transgenic GFPSlp-76 expres-
sion could not be detected in either of these cell types,
predicting a persistent loss of function in G1 rescue an-
imals. Indeed, neutrophil superoxide release in re-
sponse to fibrinogen binding in G1 rescue animals was
not detectable (Figure 2B), while CD4+ CD8+ T cells
failed to develop in the thymus of G1 rescue animals
due to a block in the transition from a CD442 CD25+ to
a CD442 CD252 phenotype identical to that observed
in Slp-76-deficient animals (Figure 2C and data not
shown; Clements et al., 1998; Pivniouk et al., 1998). Be-
cause expression of GFPSlp-76 in even a small number
of T cell progenitors would permit selective repopulation
of the thymus with mature T cells, these studies indicate
that detection of GFPSlp-76 expression by flow cytom-
etry in GATA1-GFPSlp-76 transgenic animals accurately
predicts functional rescue of Slp-76 deficiency.
GATA1-GFPSlp-76 Transgene Expression Rescues
Vascular Mixing in Slp-76-Deficient Mice
Lymphatic vessels first arise in the skin in midgestation,
and a striking pattern of blood-filled cutaneous lym-
phatics is a hallmark of midgestation embryos lacking
Slp-76 or Syk (Figure 3A; Abtahian et al., 2003). To deter-
mine whether GATA1-GFPSlp-76 transgene expression
rescued the vascular phenotype of Slp-76-deficient an-
imals, we therefore examined E14.5 G1 rescue and non-
transgenic, Slp-76-deficient littermates. G1 rescue ani-
mals appeared indistinguishable from wild-type
embryos and, in contrast to nontransgenic Slp-76-defi-
cient littermates, had no gross or histologic evidence
of blood-filled lymphatic vessels (Figure 3A).
The intestines are a site of dense lymphatic growth
due to their role in transporting absorbed dietary fats.
As a consequence of blood-lymphatic connections,
postnatal Slp-76-deficient animals develop intestinal
vascular malformations that mediate arterio-venous
shunting of blood (Abtahian et al., 2003). Most Slp-76-
deficient animals die by age 3 weeks as a result of this
vascular defect, and surviving animals exhibit marked
cardiac hypertrophy due to a chronic high-cardiac out-
put state (Abtahian et al., 2003). Postnatal G1 rescue an-
imals exhibited normal gut vasculature, normal survival,
and no evidence of cardiac hypertrophy (Figure 3C and
data not shown). Thus, all the vascular abnormalities
characteristic of Slp-76-deficient animals are corrected
by the GATA1-GFPSlp-76 transgene despite restriction
of GFPSlp-76 expression to a small number of hemato-
poietic cell types.
Syk2/2; Syk+/+ and Slp-762/2; Slp-76+/+ Chimeric
Animals Develop Focal Phenotypes Consistent with
a Cell-Autonomous Mechanism of Vascular Mixing
The ability of the GATA1-GFPSlp-76 transgene to rescue
development of the vascular phenotype is consistentwith either a cell-nonautonomous mechanism in which
circulating cells utilize Slp-76 signals to indirectly influ-
ence vascular development, or a cell-autonomous
mechanism in which Slp-76 is required in hematopoietic
cells that contribute directly to vascular development as
endothelial precursors. To distinguish between these
two possibilities, we generated chimeric animals by in-
jecting embryonic stem cells deficient in either Syk
(Syk2/2) or Slp-76 (Slp-762/2) into wild-type blastocysts
derived from ROSA26 b-galactosidase-expressing ani-
mals. In the case of a cell-nonautonomous mechanism,
the presence of wild-type circulating cells, that is, eryth-
rocytes, platelets, or eosinophils, is predicted to rescue
the vascular phenotype throughout the developing em-
bryo. In contrast, with a cell-autonomous mechanism,
the vascular phenotype is predicted to still develop to
a variable extent due to the persistent participation of
deficient endothelial precursors. Chimeric embryos
generated with either Syk-deficient or Slp-76-deficient
embryonic stem cells developed striking vascular phe-
notypes in which some regions of the embryo (e.g., the
skin overlying the upper extremity; Figure 4A) developed
blood-filled lymphatics associated with local edema,
while adjacent regions (e.g., the periorbital skin;
Figure 4A) were unaffected. Histologic analysis revealed
blood-filled LYVE1+ lymphatic vessels characteristic of
deficient embryos (Figure 4B and data not shown). Chi-
meric embryo vascular phenotypes varied widely both
between and within individual embryos but were not ob-
served in chimeric embryos generated with wild-type
ES cells (Figure S2). The presence of wild-type cells in
the tissues of animals with vascular phenotypes was
confirmed by X-gal staining and the presence of wild-
type hematopoietic cells was confirmed using the fluo-
rescent b-galactosidase substrate FDG (Figures 4C
and 4D).
Previous studies of embryos lacking Syk or Slp-76 re-
vealed heterotypic vessels containing endothelial cells
that were both positive and negative for the lymphatic
molecular marker LYVE1 at sites likely to mediate con-
nections between the blood and lymphatic circulations
(Abtahian et al., 2003). This endothelial cell phenotype
was also detected in chimeric embryos with visible vas-
cular phenotypes (Figure 4B). If deficient cells conferred
vascular mixing in a cell-autonomous manner, we rea-
soned that deficient cells should be incorporated at
such sites at a higher frequency than in apparently unaf-
fected, homotypic lymphatic vessels elsewhere in the
embryo. To positively follow deficient cell contribution
at the single-cell level, Syk-deficient ES cells were GFP
tagged using a lentiviral vector and deficient cells were
identified by immunofluorescent detection of GFP in chi-
meric embryos. GFP immunofluorescent staining re-
vealed deficient cells throughout the embryo (e.g., the
trachea; Figure 4E), and flow cytometry demonstrated
contribution to the hematopoietic cells of the fetal liver
(Figure 4F). Analysis of endothelial cells in heterotypic
vessels virtually always revealed a significant number
of deficient cells, while deficient cells were only rarely
observed in homotypic LYVE1+ vessels (29/29 versus
2/13 vessels; p < .025; see Table S1; Figure 4G). These
findings are consistent with endothelial cell-autono-
mous conferral of blood-lymphatic vascular mixing by
deficient cells.
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(A) Expression of GFPSlp-76 in hematopoietic cell lineages. GFP was assayed in bone marrow or circulating cells using the following cell surface
markers: T cells (CD90+), B cells (CD45R+), monocytes (CD11b+ and FSC/SSC profile), neutrophils (Ly-6G+ and FSC/SSC profile), natural killer
(NK) cells (NK1.1+ DX5+), dendritic cells (Ly-6G2CD11blow CD11chigh), erythrocytes (TER119+), bone marrow stem cells (CD117+ Ly-6A/E+ CD332
CD45R2 CD11b2 Ly-6G2 TER-1192), platelets (FSC/SSC), and eosinophils (CD23+ CCR3+). Mast cells were collected from the peritoneal cavity
of naı¨ve mice via saline lavage and defined as CD23+ high, CCR32 to distinguish them from eosinophils and macrophages. Red curves indicate
cells derived from GATA1-GFPSlp-76 transgenic mice and blue curves indicate wild-type cells.
(B) GFPSlp-76 is not expressed in mature endothelial cells. GFP was assayed in hematopoietic (CD45+ CD1442) and endothelial (CD452CD144+)
cells harvested from the skin of neonatal wild-type, Tie2-GFP, and GATA1-GFPSlp-76 transgenic mice. Blue boxes indicate GFP+ CD144+ en-
dothelial cells and red boxes indicate GFP+ CD45+ hematopoietic cells.
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353Syk and Slp-76 Are Expressed in Circulating
Endothelial Precursor Cells and Are Required
to Generate CEPs with Lymphatic Markers
Rescue of the vascular phenotype by the GATA1-
GFPSlp-76 transgene and the evidence that Syk and
Slp-76 are required cell autonomously during vascular
development suggested that Syk and Slp-76 might sig-
nal in a hematopoietic cell that functions as an endothe-
lial precursor. Rare cells termed circulating endothelial
precursor cells (CEPs) have been described on the basis
of molecular markers that define them as lacking CD45,
a common blood cell marker, and expressing ckit,
a stem cell marker, and VEGFR2, a receptor for vascular
endothelial growth factor required for endothelial differ-
entiation (Bertolini et al., 2003; Rafii and Lyden, 2003;
Shaked et al., 2005; Figure 5A). To determine whether
Syk and Slp-76 are expressed in CEPs, we used flow cy-
tometric detection of intracellular protein. Consistent
with previous expression studies (Chan et al., 1994;
Jackman et al., 1995), Syk was detected in B but not T
lymphocytes, while Slp-76 was detected in T but not B
lymphocytes (Figure 5B). In contrast, both Syk and
Slp-76 were detected in CEPs, but not in cells that
were CD452, VEGFR2+, and ckit2 (commonly defined
as circulating endothelial cells or CECs) (Figure 5B).
Lack of Syk and Slp-76 expression in CECs could reflect
loss of expression in more mature hematopoietic
endothelial precursors or could indicate that CECs are
nonhematopoietic endothelial cells sloughed from the
vessel wall. To distinguish between these two possibili-
ties, we analyzed CEPs and CECs derived from lethally
irradiated wild-type mice that had been reconstituted
with GFP-expressing bone marrow. GFP expression
was detected exclusively in CEPs (Figure 5C), indicating
that CEPs but not CECs are hematopoietic in origin, a
result consistent with the lack of detectable Syk and
Slp-76 expression in endothelial cells in neonatal skin
and embryonic cardinal vein (Figure S1A; Abtahian
et al., 2003). Significantly, consistent with the correction
of vascular mixing in G1 rescue animals, the GATA1-
GFPSlp-76 transgene was expressed in CEPs
(Figure 5D).
We next assessed CEPs in a cohort of the rare Slp-
76-deficient mice that survive to adulthood. CEPs were
detected in the circulating blood of 12-week-old
Slp-76-deficient animals at similar levels to that of
wild-type animals (Figure 5E). Studies have recently
suggested the presence of circulating endothelial pre-
cursors that acquire lymphatic fate (Religa et al., 2005;
Salven et al., 2003). We therefore examined the CEP
population of wild-type and Slp-76-deficient mice for
cells expressing the lymphatic molecular markers
LYVE1 and VEGFR3. A small but reproducible fractionof LYVE1+ and VEGFR3+ CEPs was detected in wild-
type mice (Figure 5A; Figure S3). Despite preserved
levels of LYVE12 and VEGFR32 CEPs, virtually no
LYVE1+ or VEGFR3+ CEPs could be detected in the
blood of Slp-76-deficient mice (Figure 5E; Figure S3B).
Consistent with a requirement for Slp-76 in these cells,
normal or supranormal levels of LYVE1+ and VEGFR3+
CEPs were detected in the blood of G1 rescue mice
(Figure 5E; Figure S3C). CEPs are believed to arise
from a population of progenitor cells in the bone marrow
that carry the same molecular markers, termed endothe-
lial progenitor cells (EPCs). In contrast to peripheral
blood CEPs, the numbers of LYVE1+ and VEGFR3+
EPCs in the bone marrow of wild-type and Slp-76-defi-
cient animals were equivalent (Figure S4). Thus, devel-
opment and rescue of the vascular phenotype follow
Syk and Slp-76 expression in CEPs and Slp-76-deficient
animals exhibit a defect in peripheral blood CEPs, re-
sults consistent with a causal role for these cells.
Discussion
In the present study, we have investigated the cellular
basis for a vascular endothelial defect that arises during
lymphatic vascular development in mouse embryos
lacking the signaling proteins Syk and Slp-76. Our find-
ings provide functional evidence that hematopoietic
cells are a source of endothelial precursors during
development.
Our conclusions are based on transgenic rescue of
gene function in knockout mice, conferral of the vascular
phenotype by deficient cells in chimeric embryos, and
studies of cognate circulating endothelial precursors in
adult animals. Functionally, we have defined the causal
cell type as a GATA1-GFPSlp-76-expressing cell that
confers blood-lymphatic vascular mixing despite the
presence of wild-type cells in chimeric embryos. Among
the differentiated hematopoietic cell lineages, GATA1-
GFPSlp-76 expression is restricted to platelets, erythro-
cytes, and eosinophils. Platelets and erythrocytes circu-
late in the blood where wild-type counterparts would be
expected to readily rescue a paracrine signal, and em-
bryos lacking platelets entirely do not develop a vascular
phenotype (Shivdasani and Orkin, 1995). In theory, a col-
lection of deficient, extravasated hematopoietic cells
could confer a ‘‘pseudoautonomous’’ phenotype in chi-
meric embryos if such cells played an essential local or
perivascular support role during lymphatic vascular de-
velopment. Such a role has been defined for perivascu-
lar macrophages and dendritic cells in induced angio-
genesis assays in adult animals (Grunewald et al.,
2006), but GATA1-GFPSlp-76 is not expressed in the
macrophage or dendritic lineages, similar vascular(C) GFPSlp-76 is expressed in embryonic blood but not endothelial cells. Single cells isolated from E14.5 GATA1-GFPSlp-76 embryos were an-
alyzed using flow cytometry as described above.
(D) Detection of GFPSlp-76 expression in embryo blood but not endothelial cells using immunohistochemistry. GFPSlp-76 was identified using
anti-GFP antibody staining of a transverse section through the descending aorta and fetal liver of an E12.5 GATA1-GFPSlp-76 transgenic em-
bryo. GFPSlp-76 expression is seen as brown staining of individual luminal blood cells (upper panel) and a subset of fetal liver cells (lower panel).
(E) GFPSlp-76 is not expressed in or around the endothelial cells of developing lymphatic vessels. Costaining for GFP (red) and the lymphatic
endothelial cell marker LYVE1 (green) was performed on sections of an E12 GATA1-GFPSlp-76 transgenic embryo. Shown is a transverse section
above the heart through the dorsal aorta (AO), cardinal vein (CV), and primitive lymph sac (LS). No GFP staining was detected in LYVE1+ endo-
thelial cells, and no GFP+ cells were detected in a perivascular location adjacent to the developing lymph sacs. The blood cells in the aorta and
cardinal vein exhibit high autofluorescence but some GFP+ luminal blood cells can be identified as strongly red-staining cells in the overlay (right
panel). The results shown are representative of three to seven individual experiments performed.
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ficient Mice
(A) Deficient glycoprotein VI (GPVI) responses in Slp-762/2 platelets are restored by the GATA1-GFPSlp-76 transgene. Platelets from wild-type
(blue bars), Slp-76-deficient (black bars), and G1 rescue (red bars) mice were exposed to convulxin (CVX), a GPVI receptor agonist, or AYPGKF
(AYP), an agonist for the G protein-coupled PAR4 receptor. Platelet activation was measured by surface expression of P-selectin after activation-
dependent granule release. Mean and standard deviation are shown, N = 4–5 for each group.
(B) Deficient Slp-762/2 neutrophil responses are not rescued by GATA1-GFPSlp-76. Neutrophils obtained from wild-type (blue), Slp-76-deficient
(black), or G1 rescue animals (red) were plated on fibrinogen after stimulation with either tumor necrosis factor a (left graph) or phorbol myristate
acetate (right graph) and release of superoxide was detected through cytochrome C oxidation. Mean and standard deviation are shown, N = 5 for
each group.
(C) Defective T cell maturation in Slp-76-deficient mice is not rescued by GATA1-GFPSlp-76. Thy1.2+ thymocytes were harvested from 10- to 12-
week-old wild-type (Slp-76+/+), Slp-76-deficient (Slp-762/2), and G1 rescue mice and stained for CD4 and CD8 as indicated. The percentage of
cells in each quadrant is shown. The results shown are representative of six independent experiments.defects do not arise in mice that lack eosinophils (Yu
et al., 2002), and, most significantly, expression analysis
of GATA1-GFPSlp-76 during early lymphatic develop-
ment failed to identify any extravascular GFP+ cells in
association with either blood or lymphatic vessels at
the time point when deficient embryos develop vascular
phenotypes. Instead, several lines of evidence supporta truly cell-autonomous mechanism. First, chimeric em-
bryos with vascular phenotypes form heterotypic ves-
sels in which LYVE12 endothelial cells are fused to
LYVE1+ endothelial cells in vessels identical to those ob-
served in deficient embryos (Abtahian et al., 2003). Such
vessels demonstrate a disproportionate incorporation of
Syk-deficient cells compared to unaffected, homotypic
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355Figure 3. The Vascular Phenotype of Slp-
762/2Mice Is Rescued by GATA1-GFPSlp-76
(A) Rescue of midgestation blood-lymphatic
mixing in G1 rescue embryos. E14.5 Slp-76-
deficient embryos with (G1 rescue) or without
(Slp-762/2) the GATA1-GFPSlp-76 transgene
are shown. Correction of vascular mixing is
demonstrated by gross and histologic ab-
sence of blood in the lymphatic vessels of
G1 rescue embryos. Black arrows, lymphatic
vessels indicated by positive immunostaining
with anti-LYVE1 antibody. Red arrows, blood
vessels indicated by negative LYVE1 immu-
nostaining. The histologic sections are of
skin at the level of the neck and chest.
(B) Rescue of mesenteric and intestinal vas-
cular mixing in G1 rescue adult mice. The
mesenteric and intestinal vasculature of 10-
week-old Slp-76-deficient (left panels) and
G1 rescue (right panels) mice are shown.
Lymphatic vessels (black arrows) are not
blood filled in G1 rescue animals. The histo-
logic sections are of intestine just below the
submucosal layers.
(C) Correction of cardiac hypertrophy in G1
rescue animals. Heart/body mass ratios
were measured at age 12 weeks. Mean and
standard deviation are shown, N = 6–9 ani-
mals per group. p values are shown for com-
parison of values obtained in G1 rescue mice
and wild-type and Slp-76-deficient mice.vessels, a result consistent with an endothelial cell-
autonomous defect. Second, endogenous Syk and
Slp-76 as well as transgenic GATA1-GFPSlp-76 are ex-
pressed in CEPs, cognate cells believed to function as
hematopoietic endothelial precursors in adult animals.
Finally, surviving Slp-76-deficient mice exhibit a defect
in their CEP population that is corrected by the
GATA1-GFPSlp-76 transgene. These findings support
the conclusion that the vascular phenotypes in deficient
and chimeric embryos arise due to a cell-autonomous
mechanism in which Syk and Slp-76 signals are required
in hematopoietic cells that become endothelial cells.
An outstanding question remains the nature of the
functional defect in hematopoietic endothelial progeni-
tors lacking Syk or Slp-76. Surviving adult Slp-76-defi-
cient animals have circulating endothelial progenitor
cells, indicating that blood-lymphatic mixing does not
arise due to simple loss of these cells. A clue to the func-
tional defect may be found in an apparent discrepancy
between the ability of wild-type cells to rescue the
vascular phenotype conferred by deficient cells in two
different experimental systems. In a previous report,
we demonstrated that cotransplanted wild-type bone
marrow rescues vascular mixing conferred by deficient
bone marrow in adult radiation chimeras (Abtahian
et al., 2003). In contrast, here we show that wild-typecells are unable to rescue vascular mixing conferred
by deficient cells during embryonic development. This
apparent difference in cell autonomy does not appear
to reflect a functional difference between adult and em-
bryonic hematopoietic cells, as chimeric fetal liver har-
vested from embryos with vascular phenotypes does
not confer a vascular phenotype when transplanted
into lethally irradiated adult animals (Figure S5). Instead,
these results are likely to reflect differences in either the
hematopoietic environment (i.e., fetal liver versus adult
bone marrow) or the nature of the angiogenic response
(i.e., vessel development versus vessel repair). A pro-
posed mechanism by which wild-type cells prevent de-
velopment of the vascular phenotype in adult radiation
chimeras but not embryo chimeras is through competi-
tive exclusion of KO cells, at the level of release into the
circulating blood and/or incorporation into peripheral
vessels (see diagram, Figure 6B). Our finding that Slp-
76-deficient animals have an abnormal peripheral blood
CEP population despite a normal bone marrow EPC
population is suggestive of a block in progenitor cell re-
cruitment/exit from the bone marrow. Syk and Slp-76
are required for transduction of integrin outside-in sig-
nals (Law et al., 1999; Mocsai et al., 2002; Newbrough
et al., 2003; Obergfell et al., 2001), and integrins mediate
both progenitor cell recruitment from the bone marrow
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(A) Chimeric E14.5 embryos generated by injection of either Syk-deficient or Slp-76-deficient ES cells into wild-type blastocysts derived from
ROSA26 mice are shown. The white arrow indicates a region of edema overlying a focal region of blood-filled lymphatics in a Syk2/2; Syk+/+ chi-
meric embryo.
(B) Identification of blood-lymphatic heterotypic vessels in chimeric embryos with vascular mixing. LYVE1 immunostaining of chimeric embryos
with visible vascular phenotypes revealed vessels composed of LYVE1+ and LYVE12 endothelial cells identical to those seen in deficient em-
bryos (Abtahian et al., 2003).
(C) Contribution of wild-type cells in a chimeric embryo demonstrated by X-gal staining. X-gal staining of the whole embryo of the Syk2/2; Syk+/+
chimeric embryo in (A) is shown.
(D) Contribution of wild-type cells to fetal liver hematopoietic tissue demonstrated by detection of b-galactosidase with the fluorescent substrate
FDG in CD45+ hematopoietic cells. The result shown is representative of studies performed on six embryos with gross and histologic evidence of
blood-filled lymphatics.
(E) Contribution of GFP+ Syk-deficient cells in chimeric embryos generated by injection of GFP+, Syk2/2 ES cells into wild-type blastocysts. GFP
is detected as red immunofluorescence in cells of the developing trachea.
(F) Identification of GFP+, Syk2/2 cells in fetal liver hematopoietic tissue of a chimeric embryo using flow cytometry.
(G) Syk-deficient endothelial cells are found in blood-lymphatic heterotypic vessels. The contribution of Syk-deficient cells to vessels containing
LYVE1+; LYVE12 heterotypic (top and bottom panels) and LYVE1+ homotypic endothelium (middle panel) was determined using dual immuno-
fluorescent staining for GFP (red) and LYVE1 (green). Note the presence of blood cells (asterisk) in heterotypic vessels (found in regions of the
embryo with vascular mixing) but not in homotypic vessels (found in regions of the embryo without vascular mixing). The vessels shown are rep-
resentative of 27 heterotypic and 13 homotypic vessels examined in three embryos.
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(A) Flow cytometric identification of circulating endothelial precursors (CEPs). The strategy to identify CEPs from total peripheral blood mono-
nuclear cells (PBMCs) using cell surface markers is shown. The boxed cell population identifies the population of cells selected by each gate. The
far right panel shows LYVE1 expression in a population of CD452, ckit+, VEGFR2+ CEPs.
(B) Syk and Slp-76 are expressed in CEPs but not circulating endothelial cells (CECs). In lymphocytes, Syk is detected in B (black lines) but not T
(green lines) cells, while Slp-76 is detected in T but not B cells (top panels). Background staining of lymphocytes obtained using an isotype-
matched control antibody is shown in gray. Both Syk and Slp-76 are expressed in CD452; VEGFR2+; ckit+ CEPs, but not in CD452; VEGFR2+;
ckit2 CECs (bottom panels).
(C) CEPs but not CECs are hematopoietic. CEPs and CECs were isolated from animals that had been lethally irradiated and reconstituted with
GFP-expressing marrow to test for hematopoietic origin.
(D) The GATA1-GFPSlp-76 transgene drives GFPSlp-76 expression in CEPs.
(E) Slp-76 is required to generate LYVE1+ CEPs. Total, LYVE12, and LYVE1+ CEPs were measured in the blood of wild-type (blue bars, n = 7), Slp-
76-deficient (black bars, n = 6), and G1 rescue (red bars, n = 7) mice. Mean and standard deviation are shown. *p = 0.001 by Student’s t test.(Papayannopoulou and Nakamoto, 1993; Papayanno-
poulou et al., 1998) and precursor cell homing to the
vasculature (Jin et al., 2006). Progenitor cell release
from the bone marrow is a complex event that requires
transmigration from the osteal zone to the vascular
zone and across the bone marrow sinusoidal endothe-
lium (Heissig et al., 2002). While little is known regardingcellular egress from the fetal liver, because that organ is
less structured and complex than bone marrow it is pos-
sible that a migration defect that confers a competitive
advantage to wild-type cells in the adult bone marrow
would not do so in the fetal liver. Such a migration defect
might also explain the connections made between
blood and lymphatic vessels, as blood-borne
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ing Conferred by Hematopoietic Endothelial
Precursors Lacking Syk or Slp-76
(A) A model by which hematopoietic endothe-
lial progenitor cells lacking Syk or Slp-76 cre-
ate blood-lymphatic connections is shown.
Endothelial progenitors from the fetal liver
or bone marrow must enter and then exit
the blood vascular system to contribute to
lymphatic vessel growth or repair. Loss of in-
tegrin signaling through Syk and Slp-76 is
postulated to hinder migration both into and
out of the blood. Incomplete exit from blood
vessels results in the formation of blood-lym-
phatic connections and heterotypic vessels
containing LYVE1+ and LYVE12 endothelial
cells.
(B) A competitive model to explain blood-
lymphatic vascular mixing in embryo chi-
meras but not adult bone marrow chimeras.
More stringent cell migration required to en-
ter the blood from the bone marrow than the
fetal liver is postulated to confer a competitive
advantage to wild-type endothelial progeni-
tors that prevents the development of vascu-
lar mixing in the adult bone marrow chimera.
The hematopoietic tissue, circulating endo-
thelial precursor cell population, and vascular
phenotype for each type of experiment are
shown. Arrow thickness indicates relative
contribution of wild-type (gray) and deficient
(black) cells to the circulating endothelial pre-
cursor pool. Arrowheads indicate blood-filled
mesenteric lymphatics and Pyers patches
in the gut of an affected adult bone marrow
chimera.endothelial precursors destined for the lymphatic sys-
tem must first completely exit the blood vascular system
and failure to do so could result in blood-lymphatic con-
nections (see model, Figure 6). Whether the vascular
phenotype in mice lacking Syk and Slp-76 arises due
to loss of signaling downstream of integrin receptors
in hematopoietic endothelial precursors is an important
area of future investigation that will require the develop-
ment of new techniques to isolate and/or generate
enough of these rare cells to directly study integrin-de-
pendent function such as migration.
Regardless of the nature of the defect, the vascular
phenotype of mice lacking Syk or Slp-76 links our
understanding of the hematopoietic-endothelial cell re-
lationship in developing and adult animals. Recently,
a significant field has emerged studying the role of he-
matopoietic precursor cells in adult angiogenesis asso-
ciated with tumor growth and vascular ischemia. Clinical
trials suggest an important role for these cells in human
vascular disease (Losordo and Dimmeler, 2004; Werner
et al., 2005), and both blocking and accelerating the re-
lease of hematopoietic endothelial precursor cells have
been proposed as novel therapies. However, the fact
that endothelial precursor cell function has been studiedprimarily using induced angiogenic responses in ani-
mals that have undergone hematopoietic reconstitution
has sparked debate over the very nature of these cells,
as well as whether they serve an equally important role
in natural angiogenic responses. Studies of mice lacking
Syk and Slp-76 provide essential evidence that hemato-
poietic endothelial precursors are genuine contributors
to vascular growth in vivo, and suggest the presence
of progenitor cell diversity that may expand both the bi-
ological role and therapeutic potential of these cells.
Experimental Procedures
Mice
Syk-deficient and Slp-76-deficient mice have been previously de-
scribed (Clements et al., 1998; Turner et al., 1995). ROSA26 and
Tie2-GFP transgenic mice were obtained from Jackson Labs.
GATA1-GFPSlp-76 transgenic mice were generated by cloning an
eGFP-Slp-76 fusion protein into the Not1 site of a GATA1 minigene
generously provided by Dr. Stuart Orkin (McDevitt et al., 1997).
Transgenic mice were genotyped by PCR using primer sequences
specific for GFP. All mice were housed under pathogen-free
conditions at the University of Pennsylvania in accordance with
National Institute of Health guidelines and approved animal
protocols.
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Surface antibodies used include anti-murine CD33 (145-2C11), CD4
(GK1.5), CD8a (53-6.7), CD11b (M1/70), CD11c (HL3), CD25 (7D4),
CD44 (1M7), CD45 (clone 30-F11), CD45R (RA3-6B2), CD90.2 (50-
2.1), CD117 (2B8), CD144 (11D4.1), flk1 (Avas 12a1), Ly-6A/E
(Sca-1, clone E13-161.7), Ly-6G (Gr-1, clone RB6-8C5), NK-1.1
(PK136), Pan-NK cells (DX5), and TER-119 (all obtained from BD
PharMingen). Polyclonal rabbit anti-mouse LYVE1 was generated
as previously described (Prevo et al., 2001). Intracellular antibodies
included mouse IgG2a anti-murine SLP-76 (clone MS76; eBio-
science) and a mouse monoclonal anti-Syk antibody generously
provided by Dr. Arthur Weiss, University of California at San Fran-
cisco (clone 5F5.2; Chu et al., 1999). Secondary antibodies in-
cluded: goat anti-mouse IgG + IgM-fluorescein isothiocyanate
(FITC) (polyclonal), mouse anti-rat IgG1/2a-biotin (clone G28-5),
streptavidin-allophycocyanin (APC), streptavidin-FITC, streptavi-
din-peridinin chlorophyll-a (Sav-PerCP) (all BD PharMingen),
APC-conjugated goat anti-mouse IgG (H+L) (Molecular Probes),
and goat anti-rabbit IgG (PharMingen).
Flow Cytometric Analysis
Blood collected from the inferior vena cava of anesthetized adult
mice was washed in collecting media (Iscove’s modified Dulbecco’s
media, 5% heat-inactivated fetal calf serum [FCS], 5 mM b-mercap-
toethanol, and 20 mM EDTA), spun down, and incubated with 1:200
dilution of purified CD16/CD32 antibody (Fc Block; BD PharMingen)
for 10 min at 4C prior to subsequent antibody stains. After the final
antibody staining, the cells were washed once more in collecting
media, spun down, and resuspended in red blood cell lysis buffer
(Becton Dickinson). For intracellular staining, cells other than
CEPs were fixed with 1% paraformaldehyde for 10 min, washed,
and resuspended in permeability buffer (2% saponin in staining me-
dia) for 10 min at room temperature. CEPs were permeabilized and
fixed by addition of 1 ml ice-cold methanol. After permeabilization,
cells were stained with a 1:50 concentration of anti-murine Syk
monoclonal antibody or anti-murine Slp-76 antibody. Goat anti-
mouse FITC was used as a secondary antibody. Cells were stained
according to standard protocols and examined on a Becton Dickin-
son FACS Caliber or Becton Dickinson LSRII cytometer. FlowJo
software (Tree Star) was used to analyze the data. When analyzing
CEPs, a minimum of 1,500,000 cells was collected per sample; a min-
imum of 60 CD452 flk1+ CD117+ cells had to be acquired to be in-
cluded in this study.
Platelet Signaling Studies
Platelets were isolated from anesthetized adult mice as previously
described (Chen and Kahn, 2003). Washed platelets (1 3 106) were
stimulated with convulxin (CVX; Alexis Biochemicals), AYPGKF (Uni-
versity of Pennsylvania Protein Chemistry Laboratory), or ADP
(Chronolog) in the presence of PE-conjugated anti-murine CD62P
antibody (BD PharMingen) for 20 min at 37C and P-selectin surface
expression was quantified by flow cytometry.
Measurement of Neutrophil Respiratory Burst
Bone marrow-derived neutrophils were isolated as previously de-
scribed (Newbrough et al., 2003). Ninety-six-well Immulon 4 HBX
plates (Thermo Labsystems) were coated with 150 mg/ml fibrinogen
(Sigma) in PBS, 15 mg/ml poly-RGD (Sigma) in PBS, or 20 mg/ml anti-
CD18 (C71/16) in carbonate buffer. Antibody-coated wells were
blocked with 10% FCS for 30 min. One hundred microliters of pre-
warmed neutrophils suspended at 4 3 106 cells/ml in Hank’s bal-
anced salt solution, 10 mM HEPES, 100 mM ferricytochrome C
(Sigma Aldrich), and 1 mM Ca2+ was added to the wells. Adherent re-
spiratory burst was measured through oxidation-induced changes
in ferricytochrome C absorbance as previously described (New-
brough et al., 2003). When indicated, 50 ng/ml murine TNFa, 10 mM
fMLP, or 100 nM PMA was added.
Neonatal Skin Cell Preparation
Neonatal skin was minced, and resuspended in a 10 ml volume of
Dispase (BD Biosciences) and collagenase P (Sigma). The samples
were incubated for 1 hr at 37C with shaking, followed by a passage
through two 70 mm nylon cell strainers (BD Falcon). The cell suspen-sions were washed twice with staining media and stained as
described.
Histology and Immunohistochemistry
Tissues were fixed in 2% paraformaldehyde, and paraffin-embed-
ded sections were studied as described at http://www.uphs.
upenn.edu/mcrc/histology/histologyhome.html. Dual staining for
GFP was accomplished using goat anti-LYVE1 (R&D Systems) and
rabbit anti-GFP (Research Diagnostics).
Generation of Chimeric Embryos
Chimeric embryos were generated by injecting Syk-deficient and
Slp-76-deficient embryonic stem cells into blastocysts harvested
from ROSA26 mice using standard methods. Slp-762/2 and Syk2/2
ES cells were generated as previously described (Mortensen et al.,
1992). Individual Syk-deficient ES cell clones expressing GFP were
isolated following exposure to GFP-expressing lentivirus as previ-
ously described (Chen et al., 2006).
b-Galactosidase Staining of Chimeric Embryos
Embryos were fixed at 4C for several hours in 2% paraformalde-
hyde and then washed for 2 hr with room temperature PBS. After
the last rinse, the embryos were placed in foil-covered scintillation
vials containing staining solution (2 mM MgCl2, 5 mM K
+ ferricya-
nide, 5 mM K+ ferrocyanide, 1% NP-40, 13 PBS, and 0.1% X-gal dis-
solved in dimethylformamide) and gently rocked for 24 hr at 37C.
The embryos were then rinsed four to five times in PBS over the
course of several hours, until the yellow tint was no longer present.
The embryos were subsequently stored in 2% paraformaldehyde.
Detection of b-Galactosidase+ Hematopoietic Cells in Chimeric
Embryos
Individual embryonic fetal livers were minced and passed through
two 70 mm nylon filters to create single-cell suspensions. The cells
were then prepared according to standard protocols using fluores-
cein di-b-D-galactopyranoside (FDG) from Molecular Probes to de-
tect cells expressing b-galactosidase. Viable CD45+ cells were ana-
lyzed for fluorescein expression.
Statistics
Means and standard deviations are shown with the number of sam-
ples for each group indicated as the N. p values shown were calcu-
lated using the two-tailed Student’s t test.
Supplemental Data
Supplemental Data include one table and five figures showing addi-
tional information regarding GATA1-GFPSlp-76 transgenic mice,
Syk+/+; Syk2/2 embryo chimeras, identification and characterization
of circulating endothelial precursor cells, and comparison of pheno-
types in Syk+/+; Syk2/2 chimeric embryos and adult radiation chi-
meras and are available at http://www.developmentalcell.com/cgi/
content/full/11/3/349/DC1/.
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